Abstract
Increasing knowledge on cellular biology has permitted rapid changes in the treatment of metastatic melanoma. Until 2011, dacarbazine was the gold standard treatment at our disposal. In 2011 the treatment landscape changed dramatically with the approval by the FDA of ipilimumab and vemurafenib. These drugs use two new therapeutic approaches: immunomodulation and the targeting of mutated cellular pathways in tumor cells.
These two drugs, used as single agents have shown important increases in overall survival, unseen before in patients with advanced melanoma, but are limited by their toxicities and the appearance of acquired resistances.
In this article, we review new therapeutic options in pathway-targeted –with the arrival of MEK inhibitors - and immune based melanoma therapies –with the arrival of anti-PD1 and anti-PDL1- as well as new therapeutic strategies developed to overcome acquired resistance and diminish drug toxicities.
Keywords: anti-PD1, anti PDL1, BRAF inhibitors, combination therapies, dabrafenib, immune based therapies, ipilimumab, MEK inhibitors, melanoma, vemurafenib.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies
Volume: 15 Issue: 4
Author(s): F. Ranchon, A. Boespflug, C. Rioufol, V. Schwiertz, L. Thomas and S. Dalle
Affiliation:
Keywords: anti-PD1, anti PDL1, BRAF inhibitors, combination therapies, dabrafenib, immune based therapies, ipilimumab, MEK inhibitors, melanoma, vemurafenib.
Abstract: Increasing knowledge on cellular biology has permitted rapid changes in the treatment of metastatic melanoma. Until 2011, dacarbazine was the gold standard treatment at our disposal. In 2011 the treatment landscape changed dramatically with the approval by the FDA of ipilimumab and vemurafenib. These drugs use two new therapeutic approaches: immunomodulation and the targeting of mutated cellular pathways in tumor cells.
These two drugs, used as single agents have shown important increases in overall survival, unseen before in patients with advanced melanoma, but are limited by their toxicities and the appearance of acquired resistances.
In this article, we review new therapeutic options in pathway-targeted –with the arrival of MEK inhibitors - and immune based melanoma therapies –with the arrival of anti-PD1 and anti-PDL1- as well as new therapeutic strategies developed to overcome acquired resistance and diminish drug toxicities.
Export Options
About this article
Cite this article as:
Ranchon F. , Boespflug A. , Rioufol C. , Schwiertz V. , Thomas L. and Dalle S. , New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (4) . https://dx.doi.org/10.2174/1871520615666150101125028
DOI https://dx.doi.org/10.2174/1871520615666150101125028 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On
Current Stem Cell Research & Therapy The Bcl-2 Family as a Rational Target for the Treatment of B-Cell Chronic Lymphocytic Leukaemia
Current Medicinal Chemistry Salicylanilide Ester Prodrugs as Potential Antimicrobial Agents - a Review
Current Pharmaceutical Design The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Image-Guided Photonic Energy Deposition for Cancer Ablation and Drug Delivery
Current Medical Imaging A Systematic Review of the Molecular Mechanisms of Uranium -Induced Reproductive Toxicity
Inflammation & Allergy - Drug Targets (Discontinued) Gabapentin and Pregabalin for the Acute Post-operative Pain Management. A Systematic-narrative Review of the Recent Clinical Evidences
Current Drug Targets NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Sphingolipids as Emerging Drug Targets: Therapeutic Applications of Ceramide Analogs
Drug Design Reviews - Online (Discontinued) Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Introduction: MMPs, ADAMs/ADAMTSs Research Products to Achieve Big Dream
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews MicroRNA-Mediated Cancer Metastasis Regulation via Heterotypic Signals in the Microenvironment
Current Pharmaceutical Biotechnology LNA Antisense: A Review
Current Physical Chemistry Immunomodulatory Activity of Astragalus, Ginseng and Echinacea: From Keith Block and Mark Mead to Today, Have We Moved On?
Current Immunology Reviews (Discontinued) Lopinavir Loaded Spray Dried Liposomes with Penetration Enhancers for Cytotoxic Activity
Infectious Disorders - Drug Targets Meet Our Editorial Board Member:
Current Cancer Drug Targets